Evofem Biosciences Enters Material Definitive Agreement
Ticker: EVFM · Form: 8-K · Filed: Nov 6, 2024 · CIK: 1618835
Sentiment: neutral
Topics: material-definitive-agreement, corporate-update
Related Tickers: EVFM
TL;DR
Evofem (EVFM) signed a big deal on 10/31.
AI Summary
Evofem Biosciences, Inc. announced on October 31, 2024, the entry into a Material Definitive Agreement. The company, formerly known as Neothetics, Inc., is incorporated in Delaware and headquartered in San Diego, California.
Why It Matters
This filing indicates a significant new agreement for Evofem Biosciences, which could impact its business operations and financial standing.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities that are not yet fully understood.
Key Players & Entities
- Evofem Biosciences, Inc. (company) — Registrant
- Neothetics, Inc. (company) — Former company name
- October 31, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- San Diego, California (location) — Principal executive offices address
FAQ
What is the nature of the Material Definitive Agreement?
The filing does not specify the details of the Material Definitive Agreement, only that one was entered into on October 31, 2024.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on October 31, 2024.
What was Evofem Biosciences, Inc. formerly known as?
Evofem Biosciences, Inc. was formerly known as Neothetics, Inc.
Where is Evofem Biosciences, Inc. incorporated?
Evofem Biosciences, Inc. is incorporated in Delaware.
What is the principal executive office address for Evofem Biosciences, Inc.?
The principal executive office address is 7770 Regents Road, Suite 113-618, San Diego, California 92122.
Filing Stats: 2,413 words · 10 min read · ~8 pages · Grade level 16.2 · Accepted 2024-11-06 08:05:59
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 per share EVFM OTCQB Indicate by
Filing Documents
- form8-k.htm (8-K) — 56KB
- ex99-1.htm (EX-99.1) — 17KB
- ex99-1_001.jpg (GRAPHIC) — 24KB
- 0001493152-24-043757.txt ( ) — 286KB
- evfm-20241031.xsd (EX-101.SCH) — 3KB
- evfm-20241031_lab.xml (EX-101.LAB) — 33KB
- evfm-20241031_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EVOFEM BIOSCIENCES, INC. Dated: November 6, 2024 By: /s/ Saundra Pelletier Saundra Pelletier Chief Executive Officer